Literature DB >> 8385956

The withdrawal of temafloxacin. Are there implications for other quinolones?

R G Finch1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8385956     DOI: 10.2165/00002018-199308010-00002

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


× No keyword cloud information.
  3 in total

Review 1.  The role of temafloxacin in the community setting: an overview.

Authors:  P Ball
Journal:  J Antimicrob Chemother       Date:  1991-12       Impact factor: 5.790

Review 2.  A review of the pharmacokinetic profile of temafloxacin.

Authors:  M N Dudley
Journal:  J Antimicrob Chemother       Date:  1991-12       Impact factor: 5.790

3.  In-vitro activity of temafloxacin for gram-positive pathogens.

Authors:  J Bille; M P Glauser
Journal:  J Antimicrob Chemother       Date:  1991-12       Impact factor: 5.790

  3 in total
  5 in total

1.  Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone.

Authors:  J T Sullivan; M Woodruff; J Lettieri; V Agarwal; G J Krol; P T Leese; S Watson; A H Heller
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

Review 2.  A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.

Authors:  S J Martin; R Jung; C G Garvin
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

3.  Safety of fluoroquinolones: An update.

Authors:  L Mandell; G Tillotson
Journal:  Can J Infect Dis       Date:  2002-01

Review 4.  The role of new quinolones in the treatment of respiratory tract infections.

Authors:  R G Finch
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 5.  Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.

Authors:  J A Balfour; P A Todd; D H Peters
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.